NKTR-061 Clinical Data Presentations

• Manuscript: Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia (December 2009)

• Press Release: Amikacin Inhale shows promising results in Phase 2 Study — May 19, 2008

• Poster #9544775: American Thoracic Society — May 19, 2008

• Poster #954746: American Thoracic Society — May 19, 2008

• Poster #954714: American Thoracic Society — May 19, 2008

• Press Release: Bayer HealthCare and Nektar Therapeutics Launch Global Development and Commercialization Agreement to Fight Gram-Negative Pneumonias — August 6, 2007

• Press Release: Nektar Therapeutics Announces Phase 2a Clinical Results Regarding the use of NKTR-061 (amikacin inhale) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference — May 21, 2007

• Backgrounder: Pulmonary Antibiotics Platform

• Poster #710: Amikacin Aerosol Epithelial (ATS Data)

• Poster #718: Reduces Antibiotics (ATS Data)

• Poster #719: Amikacin Aerosol Tracheal (ATS Data)

• Poster #720: Amikacin Aerosol Safe Serum (ATS Data)